<DOC>
	<DOC>NCT00857571</DOC>
	<brief_summary>The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets</brief_summary>
	<brief_title>A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.</brief_title>
	<detailed_description />
	<criteria>Healthy male and female volunteers. Female volunteers have to be of nonchildbearing potential Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Any condition possibly affecting drug absorption (eg, gastrectomy). A positive urine drug screen.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Dose Response Bioavailability Study</keyword>
</DOC>